|Bid||17.54 x N/A|
|Ask||17.60 x N/A|
|Day's Range||17.14 - 18.40|
|52 Week Range||10.56 - 33.77|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||208.81|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK , Oct. 9, 2019 /CNW/ - Nielsen (NYSE:NSLN) and Charlotte's Web Holdings, Inc. (TSX: CWEB, OTCQX: CWBHF), jointly announced an analytic relationship between the world's leading CBD brand with the world's leading market intelligence company. Together, Nielsen and Charlotte's Web will help guide the U.S. retail market for consumer packaged goods (CPG) companies through the evolution of the CBD space. Mirroring the changing tide happening across the U.S. retail and CPG industry, this new relationship marks an open and symbiotic relationship that is forming between the emerging CBD industry and the U.S. retail and manufacturing community.
The third quarter was definitely a bumpy ride for the stock market. One could call it a roller coaster -- primarily because roller coasters usually drop you off at the same spot where you got on. The S&P 500 saw gains of just under 0.5%, the Dow Jones gained 0.75% and the Nasdaq lost a bit more than 1%.Must like the rest of the market, the Best Stocks for 2019 race didn't see a lot of lasting moves. A CBD company continues to move among the top five, a cutting-edge telahealth company holds onto second, and a direct-to-consumer retailer continues its explosive growth. There's one quarter left for big moves, but it's far from anyone's game. * Are These 10 High-Yielding S&P Dividend Stocks Traps or Treasures? Without further ado, let's get into the Best Stocks for 2019, ranked from bottom to top.InvestorPlace - Stock Market News, Stock Advice & Trading Tips 10\. Syrah Resources (SYAAF)Investor: Eric FryYear-to-Date Change Through Q3: -70%Q2 Ranking: 10The story for Syrah Resources (OTCMKTS:SYAAF) went from can it be the best stock for 2019 to can it survive 2019?It looks like it will. 2020 is a bit less likely. Beyond that…well SYAAF really needs that electric vehicle revolution to come soon.The bull thesis for Syrah is that as electric vehicles become more profitable, the companies that supply the materials needed for the cars' batteries will also take off. Graphite is an often overlooked one of these materials, and Syrah owns Balama Mine, the world's highest grade graphite mine. But the prices of these battery components didn't increase as expected.In his update, Eric Fry explained:"Despite the booming market for electric vehicles worldwide, an "echo boom" in the prices of the so-called battery metals has failed to materialize. The prices of copper, cobalt, lithium, and graphite are all languishing near three-year lows. Nickel is the lone standout among the key battery metals, as its price recently hit a new five-year high.In response to the dire conditions in the graphite market, Syrah slashed production by two-thirds last month. And there is no guarantee that this deep production cut will be the last, as the price of graphite has slumped about 15% since the start of the year."Read more about SYAFF stock here. 9\. Weibo (WB)Source: testing / Shutterstock.com Investor: Kyle WoodleyYTD Change: -23%Q2 Ranking: 9Though it's up a modest 1.84% in Q3, Chinese digital company Weibo (NASDAQ:WB) hasn't turned around just yet. It was still down 23% at the end of Q3.But Investorplace's Luke Lango believes that WB has turned around and that turnaround is here to stay:"Weibo stock has been in a secular downtrend since early 2018. But, all major signs (improving fundamentals, favorable optics, and bullish technicals) imply that this downtrend is over."The biggest challenge remaining for WB -- and all Chinese stocks? The trade war. We keep hearing from the Trump Administration that a trade deal is close, but that's about as good as having no information about trade talks at all. * 7 Important IPO Stocks to Watch for the Long Run Will things improve for WB in the coming years? Almost definitely. Will they improve before the end of 2019? Probably not. 8\. Canada Goose (GOOS)Source: rblfmr / Shutterstock.com Investor: Will AshworthYTD Change: 1%Q2 Ranking: 8Canada Goose (NYSE:GOOS) had a much better Q3 than Q2, rising over 10% and bringing it back to flat returns for 2019. The turnaround was based mostly on solid double-beat earnings report that saw revenues grow 59% and earnings grow 37% year-over-year. GOOS's wholesale business also rebounded, retaking the lead over the company's DTC business.Investors were disappointed that it was just a double beat quarter, and not a double-beat-and-raise quarter, however.And Canada Goose isn't out of the woods just yet. As Investorplace's Ashworth stated:"One class-action lawsuit filed in early September suggests that Canada Goose management failed to disclose or made misleading statements about its sourcing of down and fur.While I picked GOOS as my top stock of 2019, I too am concerned about the way it treats the animals used to source its down and fur. As an animal lover, I wouldn't stand for any ill-treatment of animals. The company denies its suppliers' abuse the animals that are used in sourcing materials for its parkas, etc. I've chosen to take them at their word."Whether or not these lawsuits have merits remains to be seen, but it is pretty clear that GOOS will not take the top spot this year.Especially once you take into account that the 10% gains of Q3 have been erased in the first two sessions of Q4.Read more about GOOS stock here. 7\. Viper Energy Partners (VNOM)Source: Shutterstock Investor: Neil GeorgeYTD Change: 10%Q2 Ranking: 8Viper Energy Partners (NASDAQ:VNOM) is an oil and gas play, but it's not a traditional one. Instead of producing either material or refining it, VNOM owns prime parts of the Permian Basin which it leases out to E&P companies. This should isolate VNOM from some of the volatility of the energy sector, and it has."Viper has generated a return through the first three quarters of 2019 of 10.81% -- well outpacing the traditional E&P companies' stocks.It has also been expanding its properties thanks to its affiliation with Diamondback Energy (NASDAQ:FANG) which founded the company through a drop-down of property assets to Viper back in 2014."The problem? The energy sector itself. The Energy Select Sector SPDR (NYSEARCA:XLE) was up 1.2% for the first nine months of 2019. So VNOM's investment thesis held true, but the energy sector is seriously lagging other stocks this year.This doesn't mean Viper Energy isn't a good stock or dividend play, but it does mean 2019 isn't its year. * 7 High Volatility Stocks to Buy as the Market Rebounds Read more about VNOM here. 6\. LyondellBasell (LYB)Source: Via LyondellBasellInvestor: Charles SizemoreYTD Change: 10%Q2 Ranking: 7LyondellBasell (NYSE:LYB) is a plastics, chemicals and refining company -- and that wasn't the right sector to be in this year. Furthermore, with just a 9x trailing P/E and 7x forward P/E, LYB is deep in value stock territory."With cheap valuations like these, you might assume that Lyondell had hit a rough patch. But nothing could be further from the truth. Gross margins and operating margins have trended higher for years, and revenues have been stable.The lack of investor interest in Lyondell has far less to do with company performance and far more to do with the neighborhood it's in. In a world of social media hype, a plastics, chemicals and refining company just isn't all that interesting. But as investors rotate out of the story stocks of the last decade in search of new opportunities, they're likely to give reliable dividend payers like Lyondell a closer look."LYB didn't win the Best Stocks for 2019 contest, but the stock is still worth a look - especially if you think value stocks will come back in 2020.Read more about LYB here. 5\. Amazon (AMZN)Source: Jonathan Weiss / Shutterstock.com Investor: Readers' ChoiceYTD Change: 16%Q2 Ranking: 5Readers' Choice stock Amazon (NASDAQ:AMZN) didn't have a great quarter. Though it held onto the 5th place slot, it's actually down 10% in Q3. Right now, AMZN stock isn't even beating the S&P 500 for 2019. Maybe it's time to pick a different stock for 2020?What this loss seems to come down to is that investors are growing weary of Amazon's growth without thought for profits attitude. The strategy got AMZN to $1 trillion in market cap, so it did pay off, but it looks like investors are starting to expect a more mature company."This was highlighted earlier in Q3 when AMZN missed Q2 earnings per share expectations and plummeted nearly 12% in a few sessions. That's over $100 billion in market cap erased over a miss of 35 cents per share.This plunge was despite a revenue beat, so the message investors are sending here is clear: They expect more in profits than Amazon has been delivering."Of course, the long-term narrative for Amazon is still strong, but AMZN winning the Best Stocks for 2019 at this point depends more on the leaders taking a nose dive than several hundred billion in market cap flowing into AMZN in the next three months. * 5 Stocks Under $10 Worth the Risk Read more about AMZN here. 4\. Adobe (ADBE)Source: r.classen / Shutterstock.com Investors: John Jagerson and Wade HansenYTD Change: 22%Q2 Ranking: 4Despite holding onto 4th place, Adobe (NASDAQ:ADBE) didn't have the best Q3. It fell 8%. But one bad quarter isn't much in the scheme of things for a stock like ADBE. Adobe produces industry leading products and was one of the first companies to capitalize on the new software subscription revenue model.Can ADBE rebound from its Q3 losses and take the top spot in the Best Stocks for 2019 contest? That remains to be seen.Read more about ADBE here. 3\. Charlotte's Web Holdings (CWBHF)Source: Shutterstock Investor: Matt McCallYTD Change: 25%Q2 Ranking: 3For a third place stock, Charlotte's Web (OTCMKTS:CWBHF) has a better shot than you might think of winning the Best Stocks for 2019. One reason is that Charlotte's Web is in the very volatile pot sector. Who could forget the day Tilray (NASDAQ:TLRY) ran up to $300 from $230 and back to $150 in a single trading session? I'm not saying Charlotte's Web - or the 2019 pot sector - is nearly that volatile, but a run of 40% over three months is certainly possible.Another reason a win is still possible is Charlotte's Web's size. Other than SYAAF, CWBHF is the only one of our stocks sporting a sub-$1 billion market cap, that means less investor money is needed to move the needle. For today's $675 million market cap to hit 60% gains for the year, only about $200 million would needed to be invested in the company.We only check in with the Best Stocks once a quarter, but CWBHF has topped 100% gains twice in 2019, the last time being Aug. 5. It's as if we're just getting snapshots of a race, and that works just fine for a lot of stocks, but most stocks are much steadier than Charlotte's Web. Will the next snapshot happen on a day when Charlotte's Web has once again sprinted into first place before being overtaken again by a steadier runner? We'll have to see.Matt McCall pointed out that Charlotte's Web is well-positioned for this growth even among pot stocks:"Charlotte's Web remains one of a handful of cannabis companies that is able to turn a profit. That's huge. CWBHF is expected to earn $0.19 per share this year, followed by $0.69 in 2020 and up to $1.07 by 2021.…The stock is undervalued based on both earnings and revenue forecasts. Using the 2021 numbers, which is less than two years from now, CWBHF stock trades with P/E ratio of 14.3 and a price-to-sales of 1.67.Stocks that are in high-growth sectors such as cannabis and CBD should (and typically do) trade at valuations higher than the overall market. A P/E ratio between 40 and 50 for Charlotte's Web would be in-line with other high-growth stocks."In my opinion, Charlotte's Web has a higher chance to take the top spot than even the next stock on the list. * 7 Stocks the Insiders Are Buying on Sale Read more about CWBHF here. 2\. Teladoc (TDOC)Source: Shutterstock Investor: Jason MoserYTD Change: 37%Q2 Ranking: 2Teledoc (NYSE:TDOC) has had its ups and downs in 2019 to be sure, but the moves haven't been nearly as wild as the ones in Charlotte's Web stock. As a result, TDOC is up a very respectable 37% as of the end of Q3.Teladoc is the undisputed leader in the telehealth space. It's a company that makes it possible to seek medical attention, virtually without having to travel to a doctor's appointment. As more services and industries become digital in some way and the U.S. cries out for healthcare reform, a company at the intersection of these two things stands to profit big.And its growth is going well. As The Motley Fool's Jason Moser pointed out:"TDOC stock's second-quarter results showed us the business remains on track. There were a couple of leadership additions with Mala Murthy coming on as CFO and David Sides as COO… TDOC's revenue for the quarter came in just over $130 million -representing 24% organic growth."Moser also pointed out upcoming catalysts for TDOC:"Medicare Advantage will be a nice catalyst in the coming years as it will open them up to an opportunity as large as 20 million additional members.It also sounds like the CVS (NYSE:CVS) partnership continues to develop nicely. There was plenty of positive language on the earnings call regarding the relationship building with CVS and Aetna. Minute Clinics have expanded to 8 additional states, and the Aetna acquisition has stoked the HealthHub concept …In fact CVS plans to have 1,500 HealthHUB locations operating by the end of 2021."Will any of these catalysts hit in time for the end of 2019? That remains to be seen.Read more about TDOC here. 1\. Lululemon (LULU)Source: Richard Frazier / Shutterstock.com Investor: Louis NavellierYTD Change: 58%Q2 Ranking: 1And finally, Lululemon (NASDAQ:LULU) holds onto the top spot for the second consecutive quarter, and no one else really came close. LULU closed out Q3 a whopping 21 percentage points ahead of TDOC.Louis Navellier of Growth Investor attributes Lululemon's success to two things: being an entirely direct-to-consumer company and smart management.The first allows LULU to control costs and quality and keep close track of what customers want. LULU keeps production costs down and can release new products strategically in a way that won't leave them sitting on shelves. This lets LULU "charge a premium for quality products that are in limited supply.""The second force that keeps LULU stock chugging along is the company's smart management. The key to success here is that its management has known how to time Lululemon's growth.Lululemon hung back as its popularity grew, choosing to focus on building out its yoga business into the women's athleisure force it is today. Thanks to this, it was able to grow its reputation in a much more profitable way than simply flooding the market with stores and products. That cachet with its target market (and, thus, staying power) is a big reason I named it as my pick for the InvestorPlace Best Stocks of 2019 contest.And now, as it enters the men's space, analysts are drooling over the potential."So will LULU keep it's lead through the end of Q4 and win the whole thing? It seems likely, but nothing in the market is certain so I'm not betting against the other front runners either.Read more about LULU here.As of this writing, Regina Borsellino held no positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Best ETFs for 2019: The Race Is a Little More Gnarly Now * 7 Next-Generation Healthcare Stocks to Buy * Are These 10 High-Yielding S&P Dividend Stocks Traps or Treasures? The post Best Stocks for 2019: Q3 Was a Roller Coaster appeared first on InvestorPlace.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
BOULDER, CO , Sept. 24 2019 /PRNewswire/ - ( CSE: CWEB; OTCQX: CWBHF ) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in whole-plant CBD hemp ...
[Editor's note: This story was previously published in March 2019. It has since been updated and republished.]Often, when analysts or bloggers talk up the potential of marijuana stocks, the focus is on the consumer side of the industry. But some of the best stocks in the pot sector may be medical marijuana stocks.Indeed, it's on the medical side where growth is likely to be largest in the near term. Canada did legalize recreational marijuana last year, but investors promptly sold the news in response. Almost a year later, stocks like Canopy Growth (NYSE:CGC) and Tilray (NASDAQ:TLRY) have recently touched 52-week lows.InvestorPlace - Stock Market News, Stock Advice & Trading TipsU.S. legalization is likely to be a long slog. Attitudes are mixed in Europe -- but even in legalized markets, black market (and untaxed) operators will be able to take share.Meanwhile, approval of medical marijuana (in the U.S. and elsewhere) seems to be moving at a faster pace. In such a highly regulated market, black market and even smaller producers likely will be shut out. Quality and consistency will be key. Here, scale will matter. And those companies that win early have the best chance of becoming market leaders -- and providing big gains for investors. * 8 Dividend Stocks to Buy for a Recession As always -- and particularly in this space -- investors need to mind the risks and size of their positions accordingly. But for investors who see medical marijuana stocks as the next big thing, these three are the best stocks to buy for investors enamored with weed. Medical Marijuana Stocks to Buy: Charlotte's Web (CWBHF)Source: Kevin McGovern / Shutterstock.com Charlotte's Web (OTCMKTS:CWBHF) has become one of the leading players in CBD oil (cannabidiol). And though Charlotte's Web products are made from hemp -- at least for now -- instead of marijuana, the stock still looks like one of the best plays in the sector.InvestorPlace's Matt McCall named CWBHF (the stock also trades on the Canadian Securities Exchange under ticker CWEB) as his pick for our list of the best stocks for 2019. McCall's case makes some sense. CBD oil sales are soaring, and Charlotte's Web is a market leader. As McCall pointed out, the federal farm bill in the U.S. provided a catalyst by legalizing hemp.So far this year, Charlotte's Web stock has outperformed most recreational players, gaining 65% year-to-date. But a nearly 30% pullback from August highs creates another opportunity for an attractive entry point. Second-quarter earnings appear to have disappointed some investors, but revenue growth of 45% year-over-year and 15% quarter-over-quarter suggest the growth story remains intact.There is a risk here from U.S. Food and Drug Administration regulation, but the agency seems unlikely to be a roadblock to Charlotte's Web stock's growth. With so many customers yet to try CBD oil -- and so many existing users attached -- market growth should be huge. And while CWBHF isn't cheap from a valuation standpoint, its position as a market leader should allow it to grow into its valuation. Cronos (CRON)Source: Shutterstock Like most major cannabis plays, shares of Cronos (NASDAQ:CRON) have declined of late. CRON stock has dropped by 50% since early March.The declines may continue. CRON, like many of its peers, still isn't cheap. And it still isn't profitable. But there's a lot to like here, particularly for investors more interested in the medical side of the industry than the consumer side.To be sure, investors see Cronos as a consumer play. The $1.8 billion investment by tobacco giant Altria (NYSE:MO) brings in not only cash, but Altria's advertising expertise and distribution reach.But investors can't ignore that Cronos is a medical marijuana stock as well. In fact, it's that business that drove the majority of its revenue until recently. And it also has given the company a beachhead in multiple markets around the world, from its home market of Canada to Germany, Israel and Poland. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Cronos is looking to export medical marijuana via a joint venture in Israel. Its partnership with Gingko Bioworks aims to biologically manufacture expert cannabis strains. Those strains could be used for consumer products -- but they might also have medical applications as the effect of cannabinoids is better understood.The broader case for CRON stock is that the company isn't looking to be a producer, where management sees prices and profits likely to be minimal as supply increases. If that strategy works, it will allow Cronos to profit from higher-margin derivative sales to consumers. But that high-level expertise will also make Cronos a potential leader on the medical side as well. Aurora Cannabis (ACB)Source: ElRoi / Shutterstock.com Like CRON stock, Aurora Cannabis (NYSE:ACB) has a "falling knife" chart. ACB stock touched a seven-month low at the beginning of the month, and a rebound was undercut by a disappointing fiscal fourth-quarter report on Thursday.Given that Aurora likely will need to raise capital relatively soon, patience is probably advised here.But from a long-term standpoint, there's an attractive case here. Aurora's global reach is probably greater than that of any cannabis play at the moment. Medical sales drove just 30% of net cannabis revenue in Q4, but that figure should rise as efforts in Germany and Latin America drive growth.Aurora will in part be a consumer play, as is the case for most marijuana stocks at this point. But its medical business is already large - and growing. In fact, Aurora already serves nearly 90,000 medical marijuana patients worldwide. As that figure rises, so will Aurora's revenue. Once profitability follows -- which should be next year -- the long slide in ACB stock may finally reverse.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Value Stocks That Are Flying Under the Radar * 6 Mouth-Watering Fast Food Stocks for Growth Investors The post 3 Medical Marijuana Stocks to Buy appeared first on InvestorPlace.
As the cannabidiol (CBD) market takes off, investors look increasingly for the stocks to buy that are driving this market. The industry received a massive boost from the 2018 Farm Bill, which legalized hemp across the United States. This frees hemp companies from Schedule I restrictions, allowing them relative freedom to operate within and outside of the United States.Other more mainstream marijuana players have entered the CBD market. Canopy Growth (NYSE:CGC) grows the product and rumors abound that Aurora Cannabis (NYSE:ACB) will soon follow. However, both stocks have fallen in recent months due to compressing multiples and falling prices in dried cannabis. * 7 Momentum Stocks to Buy On the Dip Some CBD stocks have not seen dramatic stock price increases. The following stocks to buy appear well-positioned to profit CBD-focused investors:InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aphria (APHA)Source: Shutterstock Aphria (NYSE:APHA) has become the world's third-largest cannabis producer. With prices of dried cannabis in decline, CBD has become one distinct outlet for adding value. It already offers an extensive line of products. In the U.S., it has worked to build partnerships to bring CBD products to market as it awaits legal status for its marijuana-based CBD.In addition to the high capacity, APHA stock also offers a low valuation. It maintains a forward price-to-earnings (PE) ratio of around 23.7. It also trades at just over 9.5 times sales, which comes in well-below many larger peers. Moreover, Wall Street believes it will turn profitable this year. Analysts forecast four Canadian cents (three cents) per share in earnings this year and 32 Canadian cents (24 cents) per share in 2020.APHA stock has also avoided the severe decline to hit larger Canadian names in the cannabis industry. Despite giving up most gains from earlier in the year, the price of APHA has remained steady since about May. Moreover, it has logged a 20% gain since the beginning of the year. This stability should position APHA stock to recover once sentiment turns. Charlotte's Web Holdings (CWBHF)Source: Shutterstock Charlotte's Web Holdings (OTCMKTS:CWBHF) has not yet become a household name. However, that may quickly change for the Boulder, Colorado-based producer and distributor of hemp-based CBD products. With companies such as Kroger (NYSE:KR) and CVS (NYSE:CVS) stocking their products, the public should increasingly recognize Charlotte's Web as more than just a children's book.The stock suffered in August as it reported an earnings and revenue miss. Still, amid the ups and downs, the stock has risen by nearly 65% since the beginning of the year. Investors may also pick it up at a discount as it has fallen by over 23% since just before the company missed estimates.Despite the miss, revenue grew by 45.3% year-over-year. Although profits fell from the four cents per share in the same quarter last year, operating expenses nearly doubled to fund expansion. * 7 Tech Stocks You Should Avoid Now Moreover, the forward PE ratio stands at just 24, a bargain considering the price-to-sales (PS) ratio of many unprofitable cannabis stocks exceeds that figure. Furthermore, Wall Street forecasts profit growth of 58.3% this year and 263.2% the following year. Given the low valuation and massive growth coming, investors should put CWBHF stock on their stocks to buy list before it becomes better known. Curaleaf Holdings (CURLF)Source: Shutterstock Like Charlotte's Web, Curaleaf Holdings (OTCMKTS:CURLF) is another stock on the verge of becoming better known. Based in Wakefield, Massachusetts, Curaleaf produces cannabis and hemp-based CBD products for wellness.Though much of its business faces Schedule I-based restrictions, it has managed to establish operations in 12 states. Still, with hemp-based CBD, they have the segue needed to go nationwide no matter what happens with marijuana laws.Moreover, the market seems intent on pushing CURLF stock higher. Despite a recent earnings and revenue miss, Curaleaf stock rose on a 231.2% increase in revenue year-over-year. Furthermore, despite volatility in the equity, CURLF stock has risen by almost 60% year-to-date. It has also begun to recover from a downturn in the stock that saw its value fall by about 43% between early May and mid-July.Admittedly, multiples offer a mixed picture. A PS ratio of 25.3 makes this one of the more expensive CBD stocks to buy. Also, it will need loosened Schedule I restrictions to achieve its potential. However, with it trading below its book value, investors should consider CURLF stock before it becomes more recognized. CV Sciences (CVSI)Source: Shutterstock CV Sciences (OTCMKTS:CVSI) is the leading CBD oil maker in the U.S. It sells CBD-based products under its PlusCBD brand. The San Diego-based company also runs a specialty pharmaceuticals division that produces CBD products to treat specific medical conditions.The company continues to position itself for expansion as it has begun construction on a 45,500 sq. ft. facility in the San Diego area. This will allow the company to increase production by an estimated 500%.CVSI stock earned a profit last year of nine cents per share. Despite rising revenue, it will swing to an estimated loss of four cents per share this year as the company invests in expansion. However, this should not take CVSI off of any stocks to buy list. Wall Street predicts a profit of 13 cents per share next year. * 7 Discount Retail Stocks to Buy for a Recession CV Sciences stock has lost about 25% of its value since the beginning of the year. Still, CVSI should become one of the stocks to buy hinges on its valuation. Despite the massive growth, CV Sciences trades at about 24.2 forward earnings and less than 5.2 times company sales. With revenue and sales set to spike, this makes CVSI stock look like a buying opportunity, not one investors should unload. GW Pharmaceuticals (GWPH)Source: Shutterstock GW Pharmaceuticals (NASDAQ:GWPH) has built its future on prescription-based CBD products. It manufactures Epidyolex, the first CBD-based drug approved by the Food and Drug Administration (FDA). By taking this step, it made itself a leader in prescription-based CBD products. Now that its other drug, Sativex, is now on the market in several countries, its prospects should only improve.At a forward PE ratio of almost 111 and trading at more than 31 times sales, GWPH may not look like it belongs on any stocks to buy list. However, Wall Street expects the company to turn profitable next year. It also forecasts 93.4% earnings growth in fiscal 2019 and 295.2% the following year.I recommended a buy on GWPH stock at $155 per share. Admittedly, that prediction may have come early. However, with the prospects for GW Pharma to lead this niche, I stand by the overall forecast.Moreover, it has seen fewer negative effects from the selloff in cannabis stocks than larger peers. Although it has fallen by more than 27% from its 52-week high, it has still risen by about 43% year-to-date. Given the strong sales of its CBD products, expect to see revenue and profit increases in the company's pipeline. HEXO Corporation (HEXO)Source: Shutterstock HEXO (NYSE:HEXO) presents a unique opportunity in many areas of the cannabis industry, including CBD-based products. With its 30% market share in its home province of Quebec, it maintains a base from which it can move into markets in both Canada and the U.S. Moreover, with its alliance with Molson Coors (NYSE:TAP), it presents a unique opportunity in the CBD and cannabis-based beverage market.HEXO stock trades at just over $4.20 per share as of the time of this writing. It has lost about half of its value since peaking at $8.40 per share in late April. This makes HEXO somewhat risky as it has followed larger Canadian peers on a downward trend.Our own Laura Hoy likes HEXO stock but warns against holding a position going into earnings. I agree with this sentiment. However, the decline has taken its forward price-to-earnings ratio to about 47. While that may seem high amid flat growth for 2019, analysts are looking for 170.6% earnings growth for fiscal 2020. * 10 Battered Tech Stocks to Buy Now Although HEXO stock remains one of the riskier stocks to buy, its position in Quebec and its alliance with Molson Coors should give the company market niches with which it can lead in CBD and perhaps cannabis in general. Planet 13 Holdings (PLNHF)Source: Shutterstock Planet 13 Holdings (OTCMKTS:PLNHF) has made a name for itself in its home market of Las Vegas through retailing. Its Cannabis Entertainment Complex, otherwise known as the "Superstore," attracted a record number of visitors in August.But aside from its gaining fame as a retailer, it also happens to produce CBD. In May, Planet 13 announced the introduction of its Planet M CBD brand. They made this available at its Superstore, the Fashion Show Mall, with plans to expand to other retail outlets. They also made Planet M available online.This strategy appears effective. Analysts believe that this is one of the stocks to buy in large part because it will probably turn a profit this year. Earnings should grow quickly from there. Analysts predict an increase of 118.2% this year and a staggering 450% in fiscal 2020. Despite the massive growth, it trades at only 17.5 times forward earnings and just over 16.1 times sales.PLNHF stock has stagnated since May, trading in a range between $1.80 and $2.20 per share. However, it has not suffered the decline seen in most other cannabis stocks. It has also risen by around 107% since the beginning of the year.As the Superstore increasingly becomes a destination for cannabis shoppers, it should not only bolster sales of CBD products, but it should also boost the growth of PLNHF stock.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Momentum Stocks to Buy On the Dip * 7 Dow Titans Breaking Higher * 5 Growth Stocks to Sell as Rates Move Higher The post 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars appeared first on InvestorPlace.
Cannabis stocks and exchange traded funds endured a summer of woe. The actively managed AdvisorShares Pure Cannabis ETF (NYSE: YOLO ) is saddled with a third-quarter loss of 18.55%, but the fund's manager, ...
Vertically integrated cannabis company 48North Cannabis Corp. (TSXV: NRTH), announced Thursday it has secured 1,000,000,000 mg of active CBD oil from Iverson Family Farms Inc. via contract. Per the contract, Iverson is supposed to harvest industrial hemp on 33 acres of land this year in order to supply 48North with high-quality active CBD oil. The Company is laser-focused on securing robust distribution channels, further building and maintaining brand loyalty, and developing an innovative and diverse product offering for the increasingly competitive recreational cannabis market globally," Alison Gordon, CEO of 48North, said in a statement.
TORONTO , Sept. 12, 2019 /CNW/ - 48North Cannabis Corp. ("48North" or the "Company") (NRTH.V), is pleased to announce that it has secured 1,000,000,000 mg of high-quality active CBD oil from Iverson Family Farms Inc. ("Iverson") based in Willamette Valley, Oregon through an industrial hemp production contract. Under the terms of the contract, Iverson will harvest industrial hemp on 33 acres of land in 2019 for 48North for the purposes of providing the Company with high-quality active CBD oil. Announced on the heels of the Company's expansion into the United States , the Company intends on leveraging the high-quality active CBD oil to solidify and expand its U.S business operations.
North American cannabis sales are set to surpass $47 billion in less than five years, according to Prohibition Partners.
August 15 was not a good day for investors in Charlotte's Web (OTC:CWBHF) stock. Hopefully you weren't heavily allocated when the shares slid 6.6% and the stock message boards were overrun with bears -- many of them Charlotte's Web stock bulls just a day prior.Source: Shutterstock The culprit behind the sudden sentiment change? Second-quarter earnings. Though CWBHF saw huge revenue jumps from past quarters, those jumps fell short consensus estimates. Nonetheless, I suspect that a turnaround is imminent for Charlotte's Web stock and the bears will go back into hibernation -- and I've got more than a gut feeling to back up my bullish outlook. Detailing the Bear Raid on CWBHF StockIn the case of Charlotte's Web stock, I see this as a market overreaction to heightened analyst expectations. Sure, there's also the fact that the cannabis market as a whole declined throughout the summer, but it's the post-earnings drop that pressured a lot of weak hands to bail on CWBHF stock.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy for September So, let's break it down: as reported by the company for the second quarter of 2019, Charlotte's Web's revenues increased by a whopping 45% year-over-year to $25 million (in American dollars, not Canadian). You'd think that 45% would have been more than enough revenue growth, but analysts were expecting the dollar figure to be $27.8 million, so the bar was set quite high -- too high, in my humble opinion.I'm equally impressed with the second-quarter increase in Charlotte's Web's growing capacity. As the company has reported, the total number of acres of cannabis planted increased to 862 this year, representing 182% more than the already considerable 300 acres planted last year. As a point of reference, the 300 acres' worth of cannabis planted by Charlotte's Web in 2018 produced an astounding 675,000 pounds of salable hemp product. A Little Giant in the CBD SpaceAnd so, while the analysts and naysayers weren't impressed, I liked the numbers I saw with Charlotte's Web's earnings release. Sure, it's not the biggest cannabis company or even the largest CBD-focused company, but Charlotte's Web has been growing by leaps and bounds and that's the stuff that stock-market wealth is made of.Indeed, with giant retailers like CVS (NYSE:CVS) and Kroger (NYSE:KR) stocking the company's products on their shelves, I expect Charlotte's Web to become a household name in the near future. I can just see it now: soccer moms picking up a batch of Charlotte's Web CBD oil, capsules, or gummies along with their milk and eggs…That might sound humorous, but it's not as outlandish as you might think. Deanie Elsner, the CEO of Charlotte's Web, clearly envisions the mainstreaming of the company's CBD products as an imminent event:"We have been experiencing increased sales through both our e-commerce and retail sales channels. Top-tier mass retailers are entering the market as several national grocery and drugstore brands have announced their CBD plans. The majority of these are now carrying Charlotte's Web products. This is a significant development for the hemp CBD category." Delivering CBD to Your Doorstep… And Value to ShareholdersBut don't get the wrong idea -- Charlotte's Web's future isn't just about getting the company's products on store shelves. Perusing the company's website, there's little doubt that Charlotte's Web is pushing hard for online shopping and home delivery, along with its subscription service -- a shopping feature that millennial consumers have become accustomed to.The Charlotte's Web Autoship Program is, I must admit, hard to resist: a 10% discount on subscription orders, free two-day shipping on the first order, and every seventh order is free. Granted, the company's CBD products aren't the cheapest on the market, but I've never heard anyone complain about the quality, and Charlotte's Web's proprietary hemp genetics simply can't be replicated by competitors. * 7 Industrial Stocks to Buy for a Strong U.S. Economy The Bottom Line on Charlotte's Web StockThere's no shortage of cannabis stock to choose from, and I won't deny that there's competition in the CBD product niche. Still, with interest from well-established retailers and a savvy subscription service for online shoppers, Charlotte's Web and CWBHF stock are setting up for a powerful post-summer recovery.As of this writing, David Moadel did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 3 Artificial Intelligence Stocks to Buy * 7 Industrial Stocks to Buy for a Strong U.S. Economy * 3 Beaten-Down Bank Stocks to Buy and Hold for the Long Term The post Buy the Dip Charlotte's Web Stock for a Pure Play in CBD appeared first on InvestorPlace.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
BOULDER, CO, Aug. 21, 2019 /PRNewswire/ - (TSX: CWEB, OTCQX: CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in whole-plant hemp CBD extract products is pleased to announce the results from its 2019 annual general and special meeting of shareholders held on August 20, 2019 in New York (the "Meeting"). Each of the matters voted upon at the Meeting is discussed in detail in the Company's Management Information Circular dated July 10, 2019 (the "Circular"), a copy of which is available on the Company's SEDAR profile at www.sedar.com. The total number of votes cast at the Meeting was 55,076,745, representing 56.57% of the total number of votes attached to the outstanding voting shares of the Company. The appointment of MNP LLP as the auditors of the Company to hold office until the close of the next annual meeting of shareholders of the Company.
Charlotte's Web Holdings (TSX: CWEB) (OTCQX: CWBHF) has named Russell Hammer as chief financial officer, effective August 15. Hammer has most recently served as an advisor in private equity investments. He has more than 30 years of finance experience in the retail, tourism and technology sectors. Hammer is the latest top-tier executive to join Charlotte's […]The post Charlotte's Web Names Hammer as CFO appeared first on Market Exclusive.
BOULDER, CO, Aug. 14, 2019 /PRNewswire/ - (TSX: CWEB, OTCQX: CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in whole-plant hemp CBD extract products with naturally occurring cannabinoids, including cannabidiol ("CBD"), is pleased to announce that Russell Hammer has joined the Company as Chief Financial Officer, effective tomorrow, August 15, 2019. Mr. Hammer, who has most recently served as an advisor in private equity investments, brings more than 30 years of finance experience in the retail, tourism and technology sectors. With his experience leading multi-billion-dollar multinational companies, he is the latest top-tier executive to join Charlotte's Web as the Company accelerates its growth and evolution into a global consumer packaged goods ("CPG") brand.
BOULDER, CO , Aug. 8, 2019 /CNW/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB, OTCQX:CWBHF), the market leader in hemp CBD extract products, announces expansion plans underway in 2019 including cultivation, production, distribution and R&D to support its forecasted sales growth. The new location enables the Company to prepare for production, distribution and R&D expansion to meet increasing demand from the consumer and national retailer channels. Charlotte's Web will commence a staged build-out of the facility during Q3-2019 and continuing over a two year period.
BOULDER, CO, July 31, 2019 /PRNewswire/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB, OTCQX:CWBHF), the market leader in hemp CBD extract products, will issue its 2019 second quarter results on August 14 before the open of trading on the Toronto Stock Exchange. A conference call to discuss the results has been scheduled for the same day at 10:00 a.m. Eastern Time. To participate in the call, please dial 1-647-427-7450 or 1-888-231-8191 approximately 10 minutes before the conference call and provide conference ID 8685806. A recording of the call will be available through August 21, 2019. To listen to the rebroadcast please dial 1-416-849-0833 and provide the same conference ID.
BOULDER, CO, July 30, 2019 /PRNewswire/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB, OTCQX:CWBHF), the market leader in hemp CBD extract products, reports an extension of its research initiative with The Center for Discovery in New York State to further develop hemp genetics for optimal growing in the region. The groundbreaking project has been helping to solidify Charlotte's Web's expansion within the Eastern Appalachian Region by determining which hemp varieties grow the best under the regional microclimates and local terrain. Now in its third year, the initiative has steered Charlotte's Web's breeding program in the production of superior varieties that will support the efforts of local farmers and position the Company for success in New York and surrounding states with similar growing conditions.